Bioventus in 2021: 5 updates to know

Biologics

Since launching its initial public offering in February, orthobiologics company Bioventus marked several notable achievements, including a multimillion-dollar acquisition.

Five updates:

1. Bioventus launched its initial public offering: 7.35 million shares of its Class A common stock priced between $16 and $18 per share.

2. Larry Chen was appointed as managing director of the company's China and Asian Pacific region. 

3. Bioventus has acquired rehabilitation solutions company Bioness for $45 million upfront consideration, with up to $65 million contingent consideration. 

4. In the first quarter of 2021, Bioventus saw year-over-year net income growth, roping in $24.5 million

5. Bioventus has launched a new allograft substitute product, Osteoamp Select Flowable. The allograft is optimal for minimally invasive surgeries and can be used in a various spine and foot and ankle procedures.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers